Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
Catabasis Pharmaceuticals (NASDAQ:CATB) announced that CEO Jill C. Milne, Ph.D., will present a corporate overview highlighting their lead program QLS-215, aimed at treating hereditary angioedema. This presentation will occur at two upcoming virtual investor conferences: the Oppenheimer Rare and Orphan Disease Summit on May 21, 2021, and the Jefferies Virtual Healthcare Conference on June 3, 2021, at 9:30 AM ET. Webcasts will be available for 30 days on the company's website.
- None.
- None.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the following upcoming virtual investor conferences:
- Oppenheimer Rare and Orphan Disease Summit. Presentations will be available on-demand on May 21, 2021.
- Jefferies Virtual Healthcare Conference on June 3, 2021 at 9:30am ET.
Webcasts of the events can be accessed from the investors section of www.catabasis.com. Archived replays will be available for 30 days following the event.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families. Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210514005065/en/
FAQ
What is Catabasis Pharmaceuticals presenting at upcoming conferences?
When will the Oppenheimer Rare and Orphan Disease Summit take place?
What time is the Jefferies Virtual Healthcare Conference?
How can I access webcasts of Catabasis Pharmaceuticals' presentations?
What is QLS-215, the lead program of Catabasis Pharmaceuticals?
